Precision medicine for prostate cancer: An international perspective

Anis A Hamid; Christopher J Sweeney; Christopher Hovens; Niall Corcoran; Arun A Azad

doi:10.1016/j.urolonc.2024.02.004

Precision medicine for prostate cancer: An international perspective

Urol Oncol. 2024 Apr 12:S1078-1439(24)00334-X. doi: 10.1016/j.urolonc.2024.02.004. Online ahead of print.

Authors

Anis A Hamid¹, Christopher J Sweeney², Christopher Hovens³, Niall Corcoran³, Arun A Azad⁴

Affiliations

¹ Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, University of Melbourne, Melbourne, Australia. Electronic address: hamida1@mskcc.org.
² South Australian Immunogenomics Cancer Institute, Adelaide, Australia.
³ Department of Surgery, University of Melbourne, Melbourne, Australia.
⁴ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

PMID: 38614920
DOI: 10.1016/j.urolonc.2024.02.004

Abstract

Greater personalization of cancer medicine continues to shape therapy development and patient selection accordingly. The treatment of prostate cancer has evolved considerably since the discovery of androgen deprivation therapy. The comprehensive profiling of the prostate cancer genome has mapped the targetable molecular landscape of the disease and identified opportunities for the implementation of novel and combination therapies. In this review, we provide an overview of the molecular biology of prostate cancer and tools developed to aid prognostication and prediction of therapy benefit. Modern treatment of advanced prostate cancer is reviewed as a paradigm of increasing precision-informed approach to patient care, and must be considered on a global scale with respect to the state of science and care delivery.

Keywords: Biomarkers; Personalized therapy; Precision medicine; Prostate cancer.

Publication types

Review